Stomach cancer is so deadly largely because it produces no reliable warning signs until it has already spread. About 36% of cases in the United States are not diagnosed until the cancer has metastasized to distant organs, and another 24% have already reached nearby lymph nodes. By the time most people learn they have it, the window for curative treatment has narrowed dramatically.
Early Symptoms Are Nearly Invisible
The core problem with stomach cancer is that early-stage disease is essentially silent. When symptoms do appear, they mimic everyday digestive complaints: bloating, mild nausea, heartburn, a vague sense of fullness after eating. These overlap almost perfectly with acid reflux, peptic ulcers, and functional dyspepsia, conditions that affect millions of people and rarely signal anything dangerous. Early stomach cancers are frequently discovered by accident, during an endoscopy performed for one of these benign conditions.
By the time symptoms become impossible to ignore, things like unintentional weight loss, persistent vomiting, difficulty swallowing, or blood in the stool, the cancer is typically advanced and often inoperable. These so-called alarm symptoms are not early warnings. They are late warnings, signaling that the disease has already progressed past the point where surgery alone can offer a cure.
The United States Has No Routine Screening
Japan began mass screening for stomach cancer in the 1960s and expanded it to all residents over 40 by 1983. South Korea launched a nationwide program in 2002. These countries catch far more cases at an early, treatable stage. The United States, where stomach cancer is less common, has never implemented a population-wide screening program. That means American patients almost always rely on symptoms to trigger a diagnosis, and as described above, symptoms arrive too late.
Only about 31% of U.S. stomach cancer cases are caught while still localized. The survival gap between catching it early and catching it late is enormous. Localized stomach cancer has a far more favorable outlook, while distant-stage disease drops to a grim prognosis that reflects the difficulty of treating cancer once it has seeded itself across the body.
It Spreads in a Way That’s Hard to Treat
Stomach cancer’s preferred route of spread makes it especially difficult to control. The most common pattern is peritoneal dissemination: cancer cells detach from the original tumor, drift through the abdominal cavity, and implant on the lining of the abdomen. This lining contains tiny lymphatic openings that act as open gates for floating cancer cells to burrow beneath the surface, establish a blood supply, and grow into new tumors. The process scatters cancer across a wide surface area rather than concentrating it in a single new mass, which makes surgical removal extremely challenging.
There is currently no standard treatment for peritoneal metastasis. Surgery can’t realistically remove thousands of tiny implants scattered across the abdominal lining, and chemotherapy has limited effectiveness against them. This pattern of spread is a major reason why advanced stomach cancer carries such a poor prognosis.
Two Types, One Much Worse
Not all stomach cancers behave the same way. The two major subtypes, classified as intestinal and diffuse, have meaningfully different outcomes. Intestinal-type stomach cancer tends to be linked to environmental risk factors like chronic infection and diet, grows in more organized clusters, and generally responds better to treatment.
Diffuse-type stomach cancer is a different disease in practice. It is highly metastatic, progresses rapidly, and is far more likely to seed the abdominal lining. A large meta-analysis found that patients with diffuse-type tumors had a 23% higher risk of death compared to those with intestinal-type tumors. Diffuse-type cancer can also infiltrate the stomach wall in a spread-out pattern rather than forming a distinct lump, making it harder to detect on imaging and harder to remove with clean surgical margins.
The Stomach’s Environment Works Against Treatment
The stomach itself creates conditions that undermine the immune system’s ability to fight cancer and reduce the effectiveness of therapy. Stomach tumors tend to be low in oxygen, a state called hypoxia. When cells are starved of oxygen, they shift to a less efficient form of energy production that floods the surrounding tissue with lactic acid. This acidified environment suppresses the immune cells, particularly the T cells, that would otherwise recognize and attack cancer.
The stomach’s naturally acidic, hormonally active environment compounds this problem. Cancer cells in the stomach can essentially hijack local metabolic conditions to shield themselves from the immune response, creating a microenvironment where both the body’s natural defenses and therapeutic drugs struggle to gain traction.
Where the Tumor Sits Matters
Cancers located at the top of the stomach, near where it meets the esophagus (the cardia region), tend to be diagnosed at a more advanced stage than cancers lower in the stomach. A large multicenter study found that cardia cancers were associated with older patients, more advanced disease at diagnosis, and lower five-year survival rates. Interestingly, when researchers compared the two locations at the same stage, survival was similar. The deadliness of cardia cancers comes not from a more aggressive biology but from the fact that they are harder to catch early, possibly because their symptoms overlap even more with acid reflux and esophageal conditions.
H. pylori Is the Dominant Risk Factor
Roughly 76% of all stomach cancers worldwide are attributable to infection with H. pylori, a bacterium that colonizes the stomach lining and triggers decades of chronic inflammation. Over time, this persistent inflammation damages the stomach’s mucosal lining, creates precancerous changes, and eventually, in a fraction of those infected, leads to cancer. The process is slow, often unfolding over 20 to 30 years, which is part of why stomach cancer typically strikes later in life.
H. pylori infection is treatable with a short course of antibiotics, and eradicating it reduces stomach cancer risk. But most people carrying the bacterium have no idea they’re infected, because the majority never develop symptoms severe enough to prompt testing. Globally, an estimated 15.6 million lifetime stomach cancer cases are projected in current birth cohorts, the vast majority tied to an infection that could, in principle, be identified and eliminated before cancer ever develops.
The Numbers Tell the Story
The five-year survival rate for stomach cancer across all stages remains below 30% in most large studies, a figure that has improved only modestly over recent decades. The fundamental problem hasn’t changed: the disease is biologically quiet in its early stages, spreads through mechanisms that resist treatment, and is diagnosed too late in the majority of patients. Countries with aggressive screening programs have demonstrated that catching stomach cancer early transforms outcomes, but for most of the world, early detection remains the exception rather than the rule.